COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer


Por: Herbst R, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge D, Winzer L, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A

Publicada: 10 oct 2022
Resumen:

ISSN: 0732183X





Journal Of Clinical Oncology
Editorial
AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 40 Número: 29
Páginas: 3383
WOS Id: 000864709100006
ID de PubMed: 35452273

MÉTRICAS